Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.37 |
| ▸ | YAP1 | P46937 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7110461 | 0.94 | CACNA1B (0.44) | CACNA1BHSD17B10MCL1MEN1KMT2A | |
| SCHEMBL7111673 | 0.92 | YAP1 (0.46) | CACNA1BHSD17B10ATMMCL1YAP1 | |
| SCHEMBL7110901 | 0.92 | MEN1 (0.43) | CACNA1BHSD17B10ATMMCL1MEN1 | |
| SCHEMBL7110470 | 0.92 | MEN1 (0.43) | CACNA1BHSD17B10ATMMCL1MEN1 | |
| SCHEMBL7105591 | 0.92 | MEN1 (0.43) | CACNA1BHSD17B10ATMMCL1MEN1 | |
| SCHEMBL7107053 | 0.91 | CACNA1B (0.45) | CACNA1BHSD17B10ATMMCL1MEN1 | |
| SCHEMBL7105221 | 0.88 | ATM (0.39) | CACNA1BHSD17B10ATMMCL1MEN1 | |
| SCHEMBL7768808 | 0.88 | CACNA1B (0.47) | CACNA1BBIRC2 | |
| SCHEMBL7109484 | 0.87 | USP21 (0.40) | CACNA1BHSD17B10ATMMCL1MEN1 | |
| SCHEMBL7105548 | 0.86 | HSD17B10 (0.39) | CACNA1BHSD17B10ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013725-A1 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-01-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013725-A1 | Amino acid derivatives | CACNA1B, SCN1A, SCN2A | CACNA1B 1/4885HSD17B10 1544/4885ATM 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.